跳至主要内容
临床试验/NL-OMON54825
NL-OMON54825招募中不适用

The effect of galacto-oligosaccharides (GOS) versus a placebo on defecation parameters and microbiota in healthy children with hard or lumpy stools - The Inside Study II

Wageningen Universiteit0 个研究点目标入组 196 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
196

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 11(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria, as considered by the researchers:
  • 1. Written informed consent obtained from parents or guardians of toddlers
  • meeting the eligibility criteria and those willing to comply with the
  • requirements of the study
  • 2. Aged 1-6 years (12 to 72 months at the day of inclusion)
  • 3. Hard or firm stools (score of 1 or 2 according to the mBSFS) for more than
  • 50% of the defecations in the past month, as reported by parents and confirmed
  • by the diary of the first week of the study.

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • - Children who suffer from FC according to the Rome IV criteria: Must include 1
  • month of at least 2 of the following in infants and children up to 4 years of
  • o 2 or fewer defecations per week
  • o History of excessive stool retention
  • o History of painful or hard bowel movements
  • o History of large-diameter stools
  • o Presence of a large fecal mass in the rectum
  • In toilet-trained children, the following additional criteria may be used:
  • o At least 1 episode/week of incontinence after the acquisition of toileting
  • o History of large-diameter stools that may obstruct the toilet
  • - Children who suffer from GI complaints, known structural GI abnormalities, or
  • previous GI surgery
  • - Any condition that would make it unsafe for the child to participate. This
  • can include developmental delays associated with musculoskeletal or neurologic
  • conditions affecting the gastrointestinal tract. Children with underlying cause
  • of defecation disorder (for example: Hirschsprung*s disease, spina bifida
  • occulta, cystic fibrosis, or gastrointestinal malformations).
  • - Children with clinically significant cardiac, vascular, liver, pulmonary,
  • psychiatric disorders, severe renal insufficiency, human immunodeficiency
  • virus, acquired immunodeficiency syndrome, hepatitis B or C or known
  • abnormalities of haematology, urinalysis, or blood biochemistry, as checked by
  • the inclusion questionnaire.
  • - Children who are lactose intolerant for whom it is expected that low doses of
  • lactose could lead to diarrhoea or children that are allergic to cow*s milk
  • (GOS is derived from cow*s milk)
  • - Children allergic to fish
  • - Use of antibiotics 4 weeks prior to the study run-in period.
  • - Children on other supplements/ medication that would affect bowel function 1
  • week prior to the study run-in. This includes e.g. breast milk, fibre
  • supplements, pre-, pro-, and synbiotics, infant formula, follow on formula or,
  • young child formula
  • - Children that participate in another clinical trial.

研究者

相似试验

The effect of galacto-oligosaccharides (GOS) versus... | 临床试验